Consensus and conflicts of multigene tests in breast cancer
LIU Yin-hua
XIN Ling
ZHAO Jing-yi
Abstract：The updates of American Society of Clinical Oncology Clinical Practice Guideline on the use of multigene panel to guide adjuvant therapy for early-stage invasive breast cancer were published in Journal of Clinical Oncology in July,2017.The focused update recommendation was to address the role of MammaPrint(R) in early breast cancer based on high level evidence.The 8th edition of AJCC cancer staging manual will be effective from January 1,2018,in which the clinical utility of multigene tests including Oncotype Dx(R) was mentioned as part of cancer staging for the first time and brought widespread attention.A number of multigene tests have been proved to be prognostic to clinical outcome and are recommended to help adjuvant therapy decision making to avoid overtreatment.However,few studies or standardized procedures focused on the indications of multigene tests can be found in China.None of the domestic multigene tests are identified or authorized by original gene companies,nor proved by clinical researches.Criterion and Guidelines need to be established before large-scale promotion of multigene tests.Otherwise,the indication of using multigene tests should be taken seriously.
Keywords：breast cancermultigene test
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 79-82 )